Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Jul 26, 2020 3:56pm
377 Views
Post# 31321148

TSX Accepted PP

TSX Accepted PPThe PP has been accepted by TSX late friday according to attached below...so I think we could hear early part of this week re halt.... the PP was to pay the auditors and then Kly was gonna request the halt to be revoked by TSX .... Kalytera 21,198,033-share private placement 2020-07-24 16:42 ET - Private Placement The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced May 19, 2020, July 15, 2020, and July 24, 2020. Number of shares: 21,198,033 shares Purchase price: 1.5 cents per share Warrants: 10,599,017 share purchase warrants to purchase 10,599,017 shares Warrant exercise price: five cents for a two-year period Number of placees: 20 placees Finder's fee: $20,000.04 cash and 1,333,336 warrants payable to Echelon Wealth Partners Inc. (The finder's fee warrants are exercisable at five cents per share within 30 months from closing.) 2020 Canjex Publishing Ltd. All rights reserved.
<< Previous
Bullboard Posts
Next >>